Sutro Biopharma, Inc. (NASDAQ:STRO)
| Market Cap | $142.77M-1.7% |
| Revenue (ttm) | $45.11M-57.3% |
| Net Income | -$155.27M+28.4% |
| EPS | -$12.62+51.5% |
| Shares Out | 16.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,896 |
| Open | $8.80 |
| Previous Close | $8.72 |
| Day's Range | $8.46 - $8.99 |
| 52-Week Range | $7.15 - $43.85 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | $51.33(+496.86%) |
| Earnings Date | Mar 22, 2027 |
About STRO
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating STRO in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 22, 2027Earnings report
$STRO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in STRO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STRO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STRO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
STRO Revenue by Segment
| Collaboration and License Agreements and Supply Agreements | $9.10M | 50.06% |
| Astellas License and Collaboration Agreement | $9.05M | 49.82% |
| Vaxcyte Agreements | $23.00K | 0.13% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New STRO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STRO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in STRO
| VTIVanguard Morningstar Total Stock Market ETF | $3.40M |
| IWMiShares Russell 2000 ETF | $3.32M |
| FESMFidelity Enhanced Small Cap ETF | $1.46M |
| VXFVanguard Extended Market ETF | $1.45M |
| VFMOVanguard U.S. Momentum Factor ETF | $1.32M |
| IWNiShares Russell 2000 Value ETF | $997.36K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from STRO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst slashed price target 58% while maintaining Outperform rating; company reported Q3 results with mixed implications amid biotech sector volatility.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| VFLQ | Vanguard U.S. Liquidity Factor ETF | 0.54% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.29% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.18% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.12% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.11% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.07% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.04% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.03% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.03% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.02% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
